Verismo Therapeutics has started enrolling patients for its STAR-101 Phase I clinical trial of SynKIR-110 for treating mesothelin-overexpressing malignant pleural mesothelioma, cholangiocarcinoma and ovarian cancer.

The trial has been initiated at the University of Pennsylvania in the US.

The multicentre study will evaluate the safety and feasibility of the investigational new drug SynKIR-110 in these tumour types.

Verismo Therapeutics co-founder and CEO Dr Bryan Kim said: “We are grateful for the opportunity to partner with distinguished researchers at the University of Pennsylvania, including Dr Janos Tanyi, Dr Andrew Haas and Dr Mark O’Hara to bring this innovative therapy to those who require it the most.”

Dr Tanyi is an associate professor of Obstetrics and Gynecology in the Perelman School of Medicine at the University of Pennsylvania, and the trial’s principal investigator.

Dr Tanyi said: “Our team is excited to be part of this clinical trial with Verismo. We are enthusiastic about the prospects of this innovative therapy and its capacity to provide new hope and improved outcomes for individuals who urgently need effective treatment options.”

Verismo is engaged in the development of new KIR-CAR platform technology.

The platform is a dual-chain CAR T cell therapy capable of maintaining antitumour T cell activity even in challenging solid tumour environments.

It is also being investigated along with other technologies to provide the next-generation multimodal targeted immunotherapy for patients in need.

The technologies include in vivo gene engineering, advanced cell manufacturing and reprogramming, combinational therapies, and even allogeneic cellular therapies.

Cell & Gene Therapy coverage on Clinical Trials Arena is supported by Cytiva.

Editorial content is independently produced and follows the highest standards of journalistic integrity. Topic sponsors are not involved in the creation of editorial content.